Effects of nicorandil combined with Danhong injection on patients with myocardial ischemia-reperfusion injury
Objective To explore the clinical efficacy of Nicorandil combined with Danhong Injection in the treatment of myocardial ischemia-reperfusion injury (MIRI). Methods A total of 108 patients with coronary heart disease who underwent percutaneous coronary intervention in Coast Guard Hospital,from January 2021 to October 2023 were prospectively selected as the study subjects. They were randomly divided into a control group (treated with nicorandil alone) and a combination group (treated with nicorandil combined with Danhong injection) using a random number table method,with 50 patients in each group. The levels of MDA,SOD,CK-MB,hs-CRP,LVEF,and CT-1 before and after treatment,as well as the clinical symptoms,clinical efficacy,and adverse drug reactions after treatment,were compared between the two groups. Results Compared with before treatment,the MDA,hs-CRP,CK-MB,and CT-1 levels in the combination group and control group decreased after treatment. And the combined group was lower than the control group (t=3.893,4.745,3.949,9.467,all P<0.05). After treat-ment,both groups showed an increase in SOD and LVEF. After treatment,the combination group showed higher levels than the control group (t=7.463,5.833,P<0.05). The improvement time of cardiac function,electrocardio-gram,and arrhythmia in the combined group was shorter than that in the control group (t=3.463,3.843,3.89,all P<0.05);the effective rate of treatment in the combined group was higher than that in the control group (85.2％ vs 53.7％,x2=12.620,P<0.05). No serious adverse drug reactions were observed in both groups. Conclusion Com-bination of nicorandil and Danhong injection can improve myocardial blood supply and function in patients with myocardial ischemia-reperfusion injury,reduce the occurrence of ischemic myocardial injury,and has high safety.
NicorandilDan Hong Zhu She YeMyocardial reperfusion injuryTreatment outcome
万方数据
维普
